Key Insights on Gross Profit: Novartis AG vs Dr. Reddy's Laboratories Limited

Pharma Giants' Profit Battle: Novartis vs Dr. Reddy's

__timestampDr. Reddy's Laboratories LimitedNovartis AG
Wednesday, January 1, 20147580100000036289000000
Thursday, January 1, 20158540300000032983000000
Friday, January 1, 20169228100000031916000000
Sunday, January 1, 20177835600000032960000000
Monday, January 1, 20187630400000034759000000
Tuesday, January 1, 20198343000000034252000000
Wednesday, January 1, 20209400900000034777000000
Friday, January 1, 202110307700000037010000000
Saturday, January 1, 202211384000000036342000000
Sunday, January 1, 202320297200000034188000000
Monday, January 1, 202416360700000038895000000
Loading chart...

Data in motion

A Tale of Two Giants: Novartis AG vs Dr. Reddy's Laboratories Limited

In the competitive landscape of the pharmaceutical industry, understanding the financial health of key players is crucial. This chart provides a fascinating insight into the gross profit trends of Novartis AG and Dr. Reddy's Laboratories Limited from 2014 to 2023. Over this period, Dr. Reddy's Laboratories has shown a remarkable growth trajectory, with its gross profit more than doubling, peaking at an impressive 202% increase by 2023. In contrast, Novartis AG has maintained a steady performance, with its gross profit fluctuating slightly but remaining within a 10% range. Notably, the data for 2024 is incomplete, highlighting the dynamic nature of financial forecasting. This comparison underscores the diverse strategies and market conditions influencing these pharmaceutical titans, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025